

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/762,304	04/16/2001	Franz Josef Meyer-Almes	P66378US0	4840
136	7590 07/02/2002			
JACOBSON HOLMAN PLLC 400 SEVENTH STREET N.W. SUITE 600			EXAMINER	
			RAWLINGS, STEPHEN L	
WASHINGTO	N, DC 20004			
			ART UNIT	PAPER NUMBER
			1642	AT
			DATE MAILED: 07/02/2002	Ø /

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/762,304	MEYER-ALMES,	MEYER-ALMES, FRANZ JOSEF			
	Office Action Summary	Examiner	Art Unit				
		Stephen L. Rawling	s, Ph.D. 1642				
Period fo	The MAILING DATE of this communication a r Reply	ppears on the cover sl	neet with the correspondence a	ddress			
THE I - Exter after - If the - If NO - Failul - Any r	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION isions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory perior to reply within the set or extended period for reply will, by statuely received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however ply within the statutory minimud will apply and will expire SIX tte, cause the application to be	m of thirty (30) days will be considered time (6) MONTHS from the mailing date of this come ABANDONED (35 U.S.C. § 133).				
1) 	Responsive to communication(s) filed on 16	: Anril 2001					
2a)□	· · · · · · · · · · · · · · · · · · ·	This action is non-final					
	<i>,</i> —			h a manita i a			
3) 🗌 Dispositi	Since this application is in condition for allow closed in accordance with the practice unde on of Claims			ne ments is			
· ·	Claim(s) 1-11 is/are pending in the application	on.					
·—	4a) Of the above claim(s) is/are withdrawn from consideration.						
	<u> </u>						
•) ☐ Claim(s) is/are rejected.						
	Claim(s) is/are objected to.						
_	Claim(s) <u>1-11</u> are subject to restriction and/o	r election requiremen	t.				
	on Papers	,					
9) 🔲 -	The specification is objected to by the Examir	er.					
10) 🔲 🗆	Γhe drawing(s) filed on is/are: a)□ acc	epted or b) dojected	to by the Examiner.				
	Applicant may not request that any objection to	the drawing(s) be held in	n abeyance. See 37 CFR 1.85(a)				
11) 🔲 🗀	The proposed drawing correction filed on	is: a)∏ approved	b) disapproved by the Exami	ner.			
	If approved, corrected drawings are required in r	eply to this Office action	1.				
12) 🔲 🗆	Γhe oath or declaration is objected to by the Ε	xaminer.					
Priority u	nder 35 U.S.C. §§ 119 and 120						
13)	Acknowledgment is made of a claim for foreign	gn priority under 35 U	.S.C. § 119(a)-(d) or (f).				
a)[☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
* S	3. Copies of the certified copies of the pri application from the International E see the attached detailed Office action for a list	Bureau (PCT Rule 17.	2(a)).	l Stage			
14) 🔲 A	cknowledgment is made of a claim for domes	stic priority under 35 L	J.S.C. § 119(e) (to a provisiona	al application).			
) The translation of the foreign language packnowledgment is made of a claim for dome	• •					
Attachmen		and of the state o	5.5.5. 33 120 GHG/01 121.				
1) Notic 2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 No	terview Summary (PTO-413) Paper Notice of Informal Patent Application (Pither: Election facsimile cover sheet.				

Application/Control Number: 09/762,304

Art Unit: 1642

DETAILED ACTION

- 1. The amendment filed April 16, 2001 in Paper No. 5 is acknowledged and has been entered. Claims 3-8 and 11 have been amended.
- 2. Claims 1-11 are pending in the application and are currently subject to restriction and an election requirement.

Election/Restrictions

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8, drawn to a method for determining the chemosensitivity of cells.

Group II, claim(s) 9-11, drawn to a kit.

4. The inventions listed as groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of group I is determining the chemosensitivity of cells.

The special technical feature of group II is producing and using a kit.

Application/Control Number: 09/762,304

Art Unit: 1642

Accordingly, groups I and II are not linked by the same or corresponding special technical feature so as to form a single general inventive concept. PCT Rules 13.1 and 13.2 only provide for a single general inventive concept comprising the first claimed product, the first claimed method for producing said product, and the first claimed method for using said product; the method in I does not use the product in group II.

5. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Claim 1 is generic to a plurality of species wherein said cells are selected from the group consisting of (a) leukemia and reference cells, (b) solid tumor and reference cells, and (c) cells of pathological organs and reference cells.

Claim 1 is generic to a plurality of species wherein said substances are selected from the group consisting of (d) chemotherapeutic and pharmaceutical agents, (e) environmental pollutants, (f) peptides, (g) nucleic acid molecules and derivatives thereof, and (h) PNAs.

Claim 1 is generic to a plurality of species wherein said measuring of caspase activity is selected from the group consisting of (i) measuring caspase substrate turnover, (j) measuring binding of antibodies or derivatives thereof to caspase, (k) measuring binding of aptamers to caspase, (l) measuring binding of proteins to educts of caspase substrates, and (m) measuring binding of proteins to products of caspase substrates.

Claim 1 is generic to a plurality of species wherein said marker is selected from the group consisting of (n) a dye portion, (o) a colloidal precious metal, (p) a radioactive isotope, and (q) a rare-earth metal chelate.

6. Applicants are required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also

Page 4

Application/Control Number: 09/762,304

Art Unit: 1642

identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

- 7. Upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, Applicants must indicate which are readable upon the elected species. MPEP § 809.02(a).
- 8. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The special technical feature of species (a) is determining the chemosensitivity of leukemia and reference cells.

The special technical feature of species (b) is determining the chemosensitivity of solid tumor and reference cells.

The special technical feature of species (c) is determining the chemosensitivity of cells of pathological organs and reference cells.

The special technical feature of species (d) is determining the chemosensitivity of cells to a chemotherapeutic or pharmaceutical agent or agents.

The special technical feature of species (e) is determining the chemosensitivity of cells to a environmental pollutant or pollutants.

Art Unit: 1642

The special technical feature of species (f) is determining the chemosensitivity of cells to a peptide or peptides.

The special technical feature of species (g) is determining the chemosensitivity of cells to a nucleic acid molecule(s) and derivative(s) thereof.

The special technical feature of species (h) is determining the chemosensitivity of cells to a PNA or PNAs.

The special technical feature of species (i) is measuring caspase substrate turnover.

The special technical feature of species (j) is measuring binding of antibodies or derivatives thereof to caspase.

The special technical feature of species (k) is measuring binding of aptamers to caspase.

The special technical feature of species (l) is measuring binding of proteins to educts of caspase substrates.

The special technical feature of species (m) is measuring binding of proteins to products of caspase substrates.

The special technical feature of species (n) is measuring a dye portion.

The special technical feature of species (o) is measuring a colloidal precious metal.

The special technical feature of species (p) is measuring a radioactive isotope.

The special technical feature of species (q) is measuring a rare-earth metal chelate.

Application/Control Number: 09/762,304

Art Unit: 1642

Accordingly, species (a)-(c), (d)-(h), (i)-(m), and (n)-(q) do not share the same or

corresponding special technical feature so as to form a single general inventive concept.

9. Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

10. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Stephen L. Rawlings, Ph.D. whose telephone number is (703)

305-3008. The examiner can normally be reached on Monday-Thursday, alternate Fridays,

8:00AM-5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony C. Caputa, Ph.D. can be reached on (703) 308-3995. The fax phone

numbers for the organization where this application or proceeding is assigned are (703) 308-

4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

Stephen L. Rawlings, Ph.D.

Examiner

Art Unit 1642

slr

July 1, 2002

AVTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 Page 6



RESTRICTION ELECTION **FACSIMILE** TRANSMISSION

DATE:	
FROM/ATTORNEY:	
FIRM:	
PAGES, INCLUDING COVERSHEET:	
PHONE NUMBER:	A
	id Me
TO EXAMINER:	
ART UNIT:	
SERIAL NUMBER:	
FAX/TBLECOPIER NUMBER: (703) 308-4315	
PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.	
COMMENTS:	
IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE	

TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 10%-OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE DOCUMENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR. PLEASE NOTIFY THE ATTORNEY LISTED HERBON IMMEDIATELY.